An experimental medication that was recently shown to slow the progression of the neurodegenerative disease amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, has now demonstrated the potential to also prolong patient survival.
Merit Cudkowicz, MD
Merit Cudkowicz, MD
Chief, Neurology Department
Director, Sean M. Healey & AMG Center for ALS
Director, Neurological Clinical Research Institute
Departments, Centers, & Programs:
15 Parkman Street
Boston, MA 02114-3117
Sean M. Healey & AMG Center for ALS at Mass General
165 Cambridge Street Suite 600
Boston, MA 02115
- MD, Harvard Medical School
- MD, Harvard Medical School/ BWH
- BS, Massachusetts General Hospital
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Neurology, American Board of Psychiatry and Neurology
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
My research activities are dedicated to the study and treatment of patients with Amyotrophic Lateral Sclerosis (ALS) and other neurological disorders. As Director of the MGH Neurological Clinical Research Institute and the Principal Investigator for the NINDS supported NeuroNEXT Clinical Coordinating center (www.neuronext.org), I design clinical trials to evaluate the safety and effectiveness of therapies that have shown promise in preclinical studies. In ALS, I co-founded an international consortium to test novel therapies in ALS, the Northeast ALS (NEALS) consortium. The NEALS consortium consists of over 128 clinical sites in the United States and Canada dedicated to performing joint academic led clinical trials in ALS.. We are leading several new trials in ALS. There is a critical need in neurology for highly trained clinical investigators who work collaboratively with basic scientists to develop new therapeutic strategies.
In 2018 we launched the Sean M. Healey & AMG Center for ALS at Mass General. This new Center is dedicated to accelerating therapy development and access to treatments for people with ALS. We are launching the first Platform Trial initiative in ALS where several treatments will be tested in one platform approach. This groundbreaking initiative will cut in half the time to develop treatments, increase by 67% ability of people to receive active treatment and cut costs of drug development by 33%. This approach, already successful in oncology, will revolutionize how treatments are developed in ALS. The Healey Center bring collaborators from around the world to work together to find treatments for people with ALS.
- Nov | 14 | 2018
Episode #14 of the Charged Podcast.
- May | 16 | 2019
Doctors have struggled for years to find an effective treatment for amyotrophic lateral sclerosis (ALS), in part because it varies greatly from patient to patient in terms of how quickly it progresses and the age of onset.
- Press Release
- Aug | 3 | 2020
First Participants Enrolled in the Groundbreaking Trial Led by the Sean M. Healey & AMG Center for ALS at Mass General
As the first ever platform trial for ALS, the HEALEY ALS Platform Trial is testing three proposed drug regimens and will add two more over the next several months.
- Press Release
- Jan | 14 | 2020
The ALS Association today announced a $3 million commitment to the first platform trial for ALS, taking place at the Sean M. Healey & AMG Center for ALS at Mass General in collaboration with the Barrow Neurological Institute and the Northeast ALS Consortium (NEALS).
- Mar | 13 | 2019
The Healey Center for ALS at Mass General Unites the World's Leading Experts to Bring Innovative Trial Approaches to the Field of ALS
Announcing one of the most promising avenues for igniting a paradigm shift in ALS therapy development: the ALS platform trial.